Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts.

Rhythm Pharmaceuticals, Inc.

Morgan Stanley analyst Michael Ulz assigned a Buy rating to Rhythm Pharmaceuticals today and set a price target of $150.00. Ulz covers the Healthca...

Rhythm Pharmaceuticals (RYTM) Receives a Buy from Morgan Stanley

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Rhythm Pharmaceuticals (RYTM), Ultragenyx Pharmaceut...

Analysts’ Top Healthcare Picks: Rhythm Pharmaceuticals (RYTM), Ultragenyx Pharmaceutical (RARE)

In a report released today, Samantha Semenkow from Citi maintained a Buy rating on Rhythm Pharmaceuticals, with a price target of $143.00. Semenkow...

Citi Remains a Buy on Rhythm Pharmaceuticals (RYTM)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Moleculin Biotech (MBRX), Addus Homecare (ADUS) and ...

Analysts Offer Insights on Healthcare Companies: Moleculin Biotech (MBRX), Addus Homecare (ADUS) and Rhythm Pharmaceuticals (RYTM)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Beam Therapeutics (BEAM), Rhythm Pharmaceuticals (RY...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Rhythm Pharmaceuticals ( ($RYTM) ) just unveiled an announcement. Rhythm Pharmaceuticals reported strong commercial and clinical momentum for the q...

Rhythm Pharmaceuticals Reports Promising Phase 2 Obesity Data

In a report released today, Derek Archila from Wells Fargo assigned a Buy rating to Rhythm Pharmaceuticals, with a price target of $155.00. Accordi...

Wells Fargo Releases a Buy Rating on Rhythm Pharmaceuticals (RYTM)

Rhythm Pharmaceuticals ($RYTM) announced an update on their ongoing clinical study. Rhythm Pharmaceuticals, Inc. is running an open-label extension...

Rhythm’s Setmelanotide Extension Study: What Long-Term Data Could Mean for RYTM

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Syndax Pharmaceuticals (SNDX) and Rhythm Pharmaceuti...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RYTM	$115.63	+3.15%	672.76K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RYTM	$115.63	+3.1%	672.76K
3
4
5
6

RYTM

RYTM

Get Rhythm Pharmaceuticals, Inc. Data in Excel

Get Rhythm Pharmaceuticals, Inc. Data in Excel